Sample list of current or past clients:

GlycoMimetics, Inc. – GlycoMimetics is an oncology-focused biotechnology company dedicated to improving the lives of patients living with orphan diseases by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates. The management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry. Since its inception, GlycoMimetics has developed a diversified product pipeline with two proprietary programs now in late-stage clinical development. Learn more at

MaxCyte – MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company’s technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 120 cell therapy programs, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit

UM Ventures – UM Ventures, the joint technology transfer initiative of University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), commercializes University of Maryland’s breakthrough discoveries, fueling the creation of innovative start-up companies and attracting industry leaders and entrepreneurs to the universities. Researchers at UMB and UMCP have created hundreds of life science innovations that are available for licensing. Our Discovery Portfolio offers a mix of cutting-edge technologies, including vaccines, therapeutics, diagnostics, devices, and software that promise to make a quantifiable impact on human health and the environment. The internationally-recognized genomics, cancer, vaccine, stem cell, pharmaceutical and bioengineering research underway at the University of Maryland provides a robust pipeline of more than 250 new innovations each year. Visit their portfolio at

Learn how PressComm PR has helped others.